SHLP3
unknown riskAlso: Small Humanin-Like Peptide 3 · SHLP-3 · mt-sRNA SHLP3
SHLP3 is a mitochondria-derived peptide from the 16S rRNA open reading frame with documented mitochondrial protective effects and an emerging focus on retinal neuroprotection, where age-related mitochondrial dysfunction is a primary driver of photoreceptor loss.
Reported Benefits
Retinal Neuroprotection
Protects photoreceptors and retinal ganglion cells from oxidative and mitochondrial stress in in vitro and rodent models.
Mitochondrial Protection
Maintains mitochondrial membrane potential, reduces ROS, and prevents apoptosis in multiple stressed cell types.
Anti-oxidative
Upregulates endogenous antioxidant defenses (SOD2, catalase) in mitochondrially stressed cells.
Mechanism of Action
SHLP3 engages the JAK/STAT3 survival pathway and activates Nrf2 nuclear translocation, upregulating antioxidant response element (ARE)-driven genes including SOD2, HO-1, and catalase. In retinal tissue, where photoreceptors have extraordinarily high mitochondrial density and oxygen consumption, SHLP3's combined STAT3 activation and Nrf2 induction addresses both apoptotic and oxidative stress mechanisms simultaneously. It also inhibits cytochrome c release downstream of mitochondrial outer membrane permeabilization.
Key Clinical Studies
Cobb LJ et al. (2016)
preclinical · Cell culture models
SHLP3 shows cytoprotective activity against oxidative stress in multiple cell lines; retinal protective effects observed in photoreceptor stress models
Sreekumar PG et al. (2021)
in vitro · Retinal pigment epithelium cell models
SHLP3 reduces oxidative stress-induced apoptosis in RPE cells with relevance to age-related macular degeneration pathways
Overview
SHLP3 is the third member of the Small Humanin-Like Peptide family encoded within the mitochondrial 16S rRNA open reading frame. Like its family members, it was initially characterized by Cobb et al. (2016) in a systematic analysis of mitochondrial genome-encoded peptides — a paper that established the SHLP concept and provided initial functional characterization for all six family members.
SHLP3 is distinguished within the family by its emerging focus on retinal neuroprotection — an application driven by the unusual mitochondrial biology of photoreceptors and retinal pigment epithelium (RPE) cells, which are among the most metabolically active cells in the human body and correspondingly vulnerable to mitochondrial dysfunction with age.
Retinal Biology Rationale
Age-related macular degeneration (AMD) and other retinal degenerative diseases are increasingly understood through the lens of mitochondrial dysfunction. Photoreceptors and RPE cells have exceptional mitochondrial density and oxygen demand. With aging, mitochondrial quality declines, ROS accumulates, and mtDNA damage increases — contributing to photoreceptor apoptosis and RPE degeneration.
SHLP3’s Nrf2-mediated antioxidant upregulation and STAT3-dependent anti-apoptotic signaling make it mechanistically relevant to this pathology. In RPE cell models exposed to oxidative stress (hydrogen peroxide, A2E — a lipofuscin component toxic to RPE), SHLP3 treatment reduced apoptotic markers and maintained mitochondrial membrane integrity. The specificity of this effect to RPE and photoreceptor cells, rather than just generic cytoprotection, is what drives the retinal focus.
Mitochondrial Protection Mechanism
Beyond the retinal application, SHLP3’s general mitochondrial protective profile is consistent across cell types. It inhibits the mitochondrial permeability transition pore (mPTP) opening under stress conditions, reduces cytochrome c release, and activates the Nrf2/ARE pathway to sustain endogenous antioxidant capacity. This profile overlaps substantially with Humanin and SHLP2, though the relative potency and receptor affinity profiles differ among family members.
Research Priority
SHLP3 has less published research volume than Humanin or SHLP6 but a more defined tissue-specific application hypothesis. The retinal neuroprotection angle provides a tractable disease model — AMD and inherited retinal dystrophies have well-validated animal models and measurable endpoints — which makes SHLP3 a logical target for further preclinical development before any human work.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
Research OnlyNot FDA-approved; no 503A listing; research compound
Safety Profile
Side Effects
- •No adverse effects identified in preclinical studies
Contraindications
- •Unknown; no human safety data available
Drug Interactions
- •Unknown; theoretical additive effect with antioxidant compounds
Primary Uses
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe SHLP3?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →